DeFinium Therapeutics Inc (DFTX) Stock Price, Quote & News

Company Profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Me...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: definiumtx.com

Address:

One World Trade Center, Suite 8500, New York, United States

Kfleischmann Jun. 9 at 2:14 AM

$CMPS well ill look at it this way, a few minths ago i would if been smiling my face off to see $10, so will stay long and strong with my shares and average. only a matter of time until this gets what it deserves and cruises up to $20, should at least be with $DFTX and will be curious to see their data, sure it will be good. durability results for $CMPS on deck.

0 · Reply

InvestmentPropertease Jun. 8 at 7:17 PM

$ATAI selling my $DFTX and increasing my position here. Time to put profits to work and now’s the perfect time 💎

2 · Reply

BuyDFTX Jun. 8 at 6:35 PM

$DFTX $30 soon 📈

0 · Reply

brunoq14 Jun. 8 at 3:31 PM

$DFTX I'm not 100% bearish. I understand why success is expected here. But there's a lot of complacency here that makes me nervous.

0 · Reply

IEN Jun. 8 at 3:20 PM

$DFTX

0 · Reply

Horseman23 Jun. 8 at 3:06 PM

$CMPS should be going green by end of day $DFTX

0 · Reply

brunoq14 Jun. 8 at 1:55 PM

$DFTX 14 trading days left in June. On one of them there will be data.

0 · Reply

Horseman23 Jun. 8 at 12:56 PM

$DFTX news would be nice right bout now

0 · Reply

zcurrency Jun. 8 at 11:36 AM

$DFTX

0 · Reply

MichaelNaussCMT Jun. 7 at 9:47 AM

$DFTX 50 sounds fair

0 · Reply

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 4:01 PM EDT - 7 days ago

Definium Therapeutics Announces New Employee Inducement Grants

May 21, 2026, 7:00 AM EDT - 18 days ago

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 19, 2026, 8:00 AM EDT - 20 days ago

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-12T12:39:53.000Z - 27 days ago

Definium Therapeutics says first patient dosed in Ascend study

May 12, 2026, 7:00 AM EDT - 27 days ago

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

2026-05-08T11:19:17.000Z - 4 weeks ago

Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler

2026-05-07T21:27:51.000Z - 4 weeks ago

Definium Therapeutics reports Q1 EPS (71c), consensus (49c)

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Definium Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Definium Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Definium Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 4 weeks ago

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:00 PM EDT - 4 weeks ago

Definium Therapeutics Slides: Corporate presentation

Apr 30, 2026, 4:01 PM EDT - 5 weeks ago

Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Definium Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 6 weeks ago

Definium Therapeutics Proxy statement: Proxy filing

2026-04-23T15:55:55.000Z - 6 weeks ago

Psychedelic: Exclusive talk with biopharma company Definium

2026-04-23T12:59:49.000Z - 6 weeks ago

Definium Therapeutics price target raised to $40 from $25 at Oppenheimer

2026-04-22T20:28:39.000Z - 6 weeks ago

Definium Therapeutics highlights advancement of DT120 ODT

Apr 22, 2026, 4:15 PM EDT - 6 weeks ago

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Apr 22, 2026, 10:00 AM EDT - 6 weeks ago

Definium Therapeutics Transcript: Investor Day 2026

Apr 22, 2026, 10:00 AM EDT - 6 weeks ago

Definium Therapeutics Slides: FY 2026

Apr 20, 2026, 2:05 PM EDT - 7 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 7 weeks ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI CMPS GHRS

Apr 20, 2026, 8:26 AM EDT - 7 weeks ago

Psychedelic stocks rally with Trump's support

ATAI CMPS GHRS

Apr 20, 2026, 8:18 AM EDT - 7 weeks ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI CMPS GHRS

2026-04-20T12:14:45.000Z - 7 weeks ago

How an Executive Order Boosted Definium Therapeutics Stock (DFTX) Today

Apr 20, 2026, 6:43 AM EDT - 7 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS ENVB GHRS HELP

Apr 18, 2026, 7:38 PM EDT - 7 weeks ago

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

2026-04-16T20:25:25.000Z - 7 weeks ago

Definium Therapeutics initiated with a Buy at Stifel

Apr 16, 2026, 3:00 PM EDT - 7 weeks ago

Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-16T10:20:22.000Z - 7 weeks ago

Definium Therapeutics price target raised to $38 from $25 at Canaccord

2026-04-10T11:00:41.000Z - 2 months ago

Definium Therapeutics initiated with an Overweight at Piper Sandler

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

2026-03-31T11:10:42.000Z - 2 months ago

Definium Therapeutics announces publication of study on general anxiety disorder

Mar 31, 2026, 7:00 AM EDT - 2 months ago

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Mar 26, 2026, 7:00 AM EDT - 2 months ago

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Mar 17, 2026, 3:30 PM EDT - 2 months ago

Definium Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 1:00 PM EDT - 3 months ago

Definium Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:10 AM EST - 3 months ago

Definium Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 3 months ago

Definium Therapeutics Slides: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 4:30 PM EST - 3 months ago

Definium Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Definium Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Definium Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:01 PM EST - 3 months ago

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

Feb 26, 2026, 4:00 PM EST - 3 months ago

Definium Therapeutics Slides: Corporate presentation

Feb 24, 2026, 7:01 AM EST - 3 months ago

Definium Therapeutics to Participate at Upcoming Investor Conferences

Feb 19, 2026, 4:01 PM EST - 3 months ago

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Jan 29, 2026, 7:00 AM EST - 4 months ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 20, 2026, 7:00 AM EST - 4 months ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 14, 2026, 5:15 PM EST - 5 months ago

Definium Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:00 AM EST - 5 months ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 12, 2026, 2:45 PM EST - 5 months ago

Definium Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Dec 18, 2025, 7:01 AM EST - 6 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 6 months ago

MindMed Announces New Employee Inducement Grant

Dec 3, 2025, 3:00 PM EST - 6 months ago

Definium Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 6 months ago

Definium Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 4:01 PM EST - 6 months ago

MindMed Announces New Employee Inducement Grants

Nov 18, 2025, 7:00 AM EST - 7 months ago

Definium Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 7 months ago

Definium Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 9, 2025, 6:00 PM EST - 7 months ago

Definium Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 4:30 PM EST - 7 months ago

Definium Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Definium Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 7 months ago

Definium Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:01 PM EST - 7 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 7 months ago

Definium Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 7:01 AM EST - 7 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 7 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 7 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 7 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 7 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Sep 19, 2025, 7:00 AM EDT - 9 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 18, 2025, 1:00 PM EDT - 9 months ago

Definium Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 3:30 PM EDT - 9 months ago

Definium Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 11:05 AM EDT - 9 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 10 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 4:30 PM EDT - 11 months ago

Definium Therapeutics Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

Definium Therapeutics Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

Definium Therapeutics Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 11 months ago

Definium Therapeutics Slides: Q2 2025

Jul 31, 2025, 4:01 PM EDT - 11 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 11 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 12, 2025, 10:00 AM EDT - 1 year ago

Definium Therapeutics Transcript: AGM 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Definium Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 1 year ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 21, 2025, 2:05 PM EDT - 1 year ago

Definium Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Slides: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 1 year ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Definium Therapeutics Proxy statement: Proxy Filing

Apr 15, 2025, 7:00 AM EDT - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 11, 2025, 3:40 PM EDT - 1 year ago

Definium Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Definium Therapeutics Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Definium Therapeutics Annual report: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Definium Therapeutics Earnings release: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 12, 2025, 9:20 AM EST - 1 year ago

Definium Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Kfleischmann Jun. 9 at 2:14 AM

0 · Reply

InvestmentPropertease Jun. 8 at 7:17 PM

$ATAI selling my $DFTX and increasing my position here. Time to put profits to work and now’s the perfect time 💎

2 · Reply

BuyDFTX Jun. 8 at 6:35 PM

$DFTX $30 soon 📈

0 · Reply

brunoq14 Jun. 8 at 3:31 PM

$DFTX I'm not 100% bearish. I understand why success is expected here. But there's a lot of complacency here that makes me nervous.

0 · Reply

IEN Jun. 8 at 3:20 PM

$DFTX

0 · Reply

Horseman23 Jun. 8 at 3:06 PM

$CMPS should be going green by end of day $DFTX

0 · Reply

brunoq14 Jun. 8 at 1:55 PM

$DFTX 14 trading days left in June. On one of them there will be data.

0 · Reply

Horseman23 Jun. 8 at 12:56 PM

$DFTX news would be nice right bout now

0 · Reply

zcurrency Jun. 8 at 11:36 AM

$DFTX

0 · Reply

MichaelNaussCMT Jun. 7 at 9:47 AM

$DFTX 50 sounds fair

0 · Reply

twiggs462 Jun. 7 at 2:32 AM

$CMPS $DFTX If Compass gets approved and Definium has clean positive Phase 3 data, I would view CMPS as plausibly worth $4B–$6B and DFTX as plausibly worth $5B–$7B at that stage. That would imply roughly $31–$46 for CMPS and $46–$64 for DFTX as a practical base-case event range, with higher upside if the market gets excited about psychedelic psychiatry as a major new category.

0 · Reply

mcgr Jun. 7 at 2:06 AM

$CMPS $ATAI $DFTX $HELP This is your friendly reminder that volatility downward right now is fantastic, and you’ll be purchasing cheaper shares at a more and more derisked stage as we fast approach phase 3 data for the others and NDA for $CMPS . It won’t happen, but I’m PRAYING for a 50% pull back in the sector right into these data drops lol.

3 · Reply

hemlock17 Jun. 6 at 8:09 PM

@leLu83 hey fuckface, why is $ATAI down YTD if it is so great? $DFTX is up 80%. I hold both. Thankfully 50x more DFTX.

0 · Reply

Rocketzz Jun. 6 at 8:00 PM

$ATAI ooof, stick to $DFTX and $CMPS . Chart not looking too good

0 · Reply

BioBum Jun. 5 at 6:34 PM

$DFTX when’s readout? It’s got to be any week, right?

2 · Reply

brunoq14 Jun. 5 at 6:31 PM

$DFTX Apparently it's another round of largely uninformed criticism of psychedelic drugs, part of the current pushback against Trump. The particular villain is ibogaine, which nobody is using.

0 · Reply